BMS-986393 (CC-95266), a G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D)-Targeted Chimeric Antigen Receptor ( CAR) T-Cell Therapy for Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results from a Phase 1 Study

被引：41

作者：

Bal, Susan ^{[1
]}

Htut, Myo ^{[2
]}

Nadeem, Omar ^{[3
]}

Larry, Anderson D., Jr. ^{[4
]}

Kocoglu, Hakan ^{[5
]}

Gregory, Tara ^{[6
]}

Rossi, Adriana C. ^{[7
]}

Martin, Tom ^{[8
]}

Egan, Daniel N. ^{[9
]}

Costa, Luciano ^{[1
]}

Hu, Hongxiang ^{[10
]}

Chen, Yanping ^{[10
]}

Li, Shaoyi ^{[10
]}

Kelly, Lisa M. ^{[10
]}

Sarkis, Naomey ^{[10
]}

Ziyad, Safiyyah ^{[10
]}

Kao, Wei-Ming ^{[10
]}

Kaeding, Allison June ^{[10
]}

Burgess, Michael R. ^{[10
]}

Berdeja, Jesus G. ^{[11
]}

机构：

[1] Univ Alabama Birmingham, Birmingham, AL USA

[2] City Hope Natl Med Ctr, Comprehens Canc Ctr, Duarte, CA USA

[3] Dana Farber Canc Inst, Boston, MA USA

[4] Simmons Comprehens Canc Ctr, Hematol Malignancies & Cellular Therapy Program, Dallas, TX USA

[5] Univ Maryland, Baltimore, MD USA

[6] Presbyterian St Lukes Med Ctr, Sarah Cannon Canc Inst, Colorado Blood Canc Inst, Denver, CO USA

[7] Icahn Sch Med Mt Sinai, Tisch Canc Inst, Dept Med Hematol & Med Oncol, New York, NY USA

[8] Univ Calif San Francisco, San Francisco, CA USA

[9] Swedish Canc Inst, Seattle, WA USA

[10] Bristol Myers Squibb, Princeton, NJ USA

[11] Sarah Cannon Res Inst, Nashville, TN USA

来源：

关键词：

D O I：

10.1182/blood-2023-181857

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：5